Efficacy and Safety of Estradiol Valerate/Dienogest for the Management of Heavy Menstrual Bleeding: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Clinical Trial

Qi Yu, Yingfang Zhou, Л. В. Сутурина, Larisa Suturina, Unnop Jaisamrarn, Dongmei Lu, Susanne Parke
Journal of women's health (2002) · 2018 · vol. 27(10) , pp. 1225–1232 · doi:10.1089/jwh.2017.6522 · PMID:29957101 · W2809861734
RCT OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This phase III trial found estradiol valerate/dienogest significantly reduced menstrual blood loss and increased hemoglobin/ferritin compared to placebo in women with heavy menstrual bleeding.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: To investigate the efficacy and safety of estradiol valerate (EV)/dienogest (DNG) for the management of heavy menstrual bleeding (HMB) in Asian and non-Asian women desiring contraception. MATERIALS AND METHODS: In this multicenter, double-blind, phase III study, women were randomized 2:1 to receive EV/DNG or placebo tablets daily for seven 28-day cycles. The primary endpoint was the absolute change in menstrual blood loss (MBL) volume between the run-in and efficacy phases (90 days each). Secondary endpoints included the proportion of women with successful treatment (i.e., no episodes of MBL ≥80 mL and a decrease of <50% in MBL), percent change in MBL from the run-in phase, and change in hemoglobin and serum ferritin levels. Adverse events (AEs) were monitored throughout the study. RESULTS: Of the 341 women (mean age 34.7 ± 7.7 years; 309 Asians, 32 non-Asians) randomized, 270 completed the study. Mean reduction in MBL volume from run-in phase was significantly greater with EV/DNG than placebo (366.75 mL vs. 149.14 mL; p < 0.0001), with ∼52% and 12% of women, respectively, experiencing successful treatment. Percent decrease in MBL volume from the run-in phase was significantly greater with EV/DNG than placebo (63.5% vs. 24.8%; p < 0.0001). Hemoglobin and serum ferritin levels were increased with EV/DNG compared with placebo. Study drug-related AEs were reported in 16.3% and 8.2% of women with EV/DNG and placebo, respectively, none of which were of severe intensity. CONCLUSIONS: EV/DNG may be a safe and effective option in the treatment of HMB in Asian and non-Asian women who desire contraception.

My notes (saved in your browser only)

MeSH descriptors

Estradiol Menorrhagia Nandrolone Adult Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Drug Combinations Estradiol Estradiol Estradiol Estrogen Replacement Therapy Estrogen Replacement Therapy Estrogens Estrogens Estrogens Female Ferritins Ferritins Hemoglobins

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

Cited by (4)

References (21)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-14T06:29:28.650500+00:00
pubmed
last seen: 2026-10-08T21:22:24.294217+00:00
unpaywall
last seen: 2026-10-11T06:28:45.473802+00:00
License: CC0 · commercial use OK